Compare Danaher Corporation (DHR) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Royal Bank of Canada — how do they compare? Danaher Corporation trades at $207 (market cap $147.18B), while Royal Bank of Canada trades at $210.44 (market cap $292.92B). The key difference: Royal Bank of Canada is the larger of the two by market cap, and Royal Bank of Canada pays the higher dividend (2.36%). Which is the better fit depends on your goals.
| DHR | RY | |
|---|---|---|
Market Cap | $147.18B | $292.92B |
Sector | Health | Financials |
52-Week High | $242.05 | $217.87 |
52-Week Low | $161.91 | $133.43 |
Enterprise Value | $169.39B | — |
Dividend Yield | 0.76% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Royal Bank of Canada (RY) trades at $211.08, down 0.17% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.84 exceeding expectations. Revenue grew to $66.53B in 2025, and net income margin improved to 31.85%. Analyst consensus is mixed, with 43% buy ratings, while recent news highlights insider selling and institutional adjustments to holdings.
RY presents a solid investment case with robust profitability and consistent earnings outperformance, though valuation ratios like P/E of 19.23 and P/B of 3.17 suggest a premium. Risks include high debt levels and macroeconomic sensitivity, but the bullish technical trend and dividend yield support a cautiously optimistic outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
